Immune responses in post kala-azar dermal leishmaniasis

Chatterjee, Mitali ; Sengupta, Ritika ; Mukhopadhyay, Debanjan ; Mukherjee, Shibabrata ; Dighal, Aishwarya ; Moulik, Srija ; Sengupta, Shilpa (2020) Immune responses in post kala-azar dermal leishmaniasis Indian Journal of Dermatology, 65 (6). p. 452. ISSN 0019-5154

Full text not available from this repository.

Official URL: http://doi.org/10.4103/ijd.IJD_258_20

Related URL: http://dx.doi.org/10.4103/ijd.IJD_258_20

Abstract

Kala-azar, commonly known as visceral leishmaniasis (VL), is a neglected tropical disease that has been targeted in South Asia for elimination by 2020. Presently, the Kala-azar Elimination Programme is aimed at identifying new low-endemic foci by active case detection, consolidating vector control measures, and decreasing potential reservoirs, of which Post Kala-azar Dermal Leishmaniasis (PKDL) is considered as the most important. PKDL is a skin condition that occurs after apparently successful treatment of VL and is characterized by hypopigmented patches (macular) or a mixture of papules, nodules, and/or macules (polymorphic). To achieve this goal of elimination, it is important to delineate the pathophysiology so that informed decisions can be made regarding the most appropriate and cost-effective approach. We reviewed the literature with regard to PKDL in Asia and Africa and interpreted the findings in establishing a potential correlation between the immune responses and pathophysiology. The overall histopathology indicated the presence of a dense, inflammatory cellular infiltrate, characterized by increased expression of alternatively activated CD68+ macrophages, CD8+ T cells showing features of exhaustion, CD20+ B cells, along with decreased CD1a+ dendritic cells. Accordingly, this review is an update on the overall immunopathology of PKDL, so as to provide a better understanding of host-parasite interactions and the immune responses generated which could translate into availability of markers that can be harnessed for assessment of disease progression and improvement of existing treatment modalities.

Item Type:Article
Source:Copyright of this article belongs to Wolters Kluwer Health, Inc.
ID Code:123587
Deposited On:07 Oct 2021 09:33
Last Modified:07 Oct 2021 09:33

Repository Staff Only: item control page